A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study

B. Van Calster, D. Timmerman, Antonia Carla Testa, L. Valentin, Cd Van Holsbeke, J Zhang, D Jurkovic, Aa Lissoni, A Czekierdowski, D Fischerova, E Domali, G Van De Putte, I Vergote, S Van Huffel, T. Bourne

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


BACKGROUND: The CA-125 tumor marker has limitations when used to distinguish between benign and malignant ovarian masses. We therefore establish likelihood curves of six subgroups of ovarian pathology based on CA-125 and menopausal status. METHODS: This cross-sectional study conducted by the International Ovarian Tumor Analysis group involved 3,511 patients presenting with a persistent adnexal mass that underwent surgical intervention. CA-125 distributions for six tumor subgroups (endometriomas and abscesses, other benign tumors, borderline tumors, stage I invasive cancers, stage II-IV invasive cancers, and metastatic tumors) were estimated using kernel density estimation with stratification for menopausal status. Likelihood curves for the tumor subgroups were derived from the distributions. RESULTS: Endometriomas and abscesses were the only benign pathologies with median CA-125 levels above 20 U/mL (43 and 45, respectively). Borderline and invasive stage I tumors had relatively low median CA-125 levels (29 and 81 U/mL, respectively). The CA-125 distributions of stage II-IV invasive cancers and benign tumors other than endometriomas or abscesses were well separated; the distributions of the other subgroups overlapped substantially. This held for premenopausal and postmenopausal patients. Likelihood curves and reference tables comprehensibly show how subgroup likelihoods change with CA-125 and menopausal status.Conclusions and Impact: Our results confirm the limited clinical value of CA-125 for preoperative discrimination between benign and malignant ovarian pathology. We have shown that CA-125 may be used in a different way. By using likelihood reference tables, we believe clinicians will be better able to interpret preoperative serum CA-125 results in patients with adnexal masses. Cancer Epidemiol Biomarkers Prev; ©2011 AACR.
Original languageEnglish
Pages (from-to)2420-2428
Number of pages9
Publication statusPublished - 2011


  • ovarian tumor pathology


Dive into the research topics of 'A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study'. Together they form a unique fingerprint.

Cite this